Clinical trial
CP-675,206 In Patients With Advanced Melanoma
NCT00086489 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00086489 |
|---|---|
| Title | CP-675,206 In Patients With Advanced Melanoma |
| Official title | Phase 1 Open Label, Non-Randomized, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Immune Function Effects, And Efficacy Of Multiple Doses Of CP-675,206 In Patients With Advanced Melanoma, And Phase 2, Open Label, Randomized Study To Evaluate the Efficacy, Safety… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | CP-675, 206 |
| Enrollment | 118 |
| Start date | Aug 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2009 |
| First posted | Jul 5, 2004 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: